Did Anadys Says Hep C Drug Shows Positive Results in Trial?”
Anadys Pharma’s Hepatitis C Drug Shows Positive Preliminary Results In Phase II – Update 12/17/2009 12:57 PM ET (RTTNews) – Thursday, Anadys Pharmaceuticals Inc. (ANDS: News ) said that its ongoing Phase II study of ANA598, showed positive preliminary results. The company said 56% of the patients receiving the drug plus SOC showed undetectable levels of virus at four weeks, compared to 20% of patients who received placebo plus SOC. In the present study for the experimental hepatitis C drug, ANA598 in combination with pegylated interferon and ribavirin or SOC was given to HCV patients at a dosage level of 200 mg bid and analysed at four weeks. Anadys noted that in the first cohort of the study 44 patients received at least one dose of study medications, 29 receiving ANA598 and 15 receiving placebo. Four patients , three genotype 1a patients receiving placebo plus SOC and one genotype 1b patient receiving ANA598 plus SOC discontinued either ANA598 or placebo at four week due to failing t
Anadys says hep C drug shows positive results in trial Thu Dec 17, 2009 8:40am EST (Reuters) – Anadys Pharmaceuticals Inc said its experimental hepatitis C drug, ANA598, showed positive preliminary results in a mid-stage trial, sending its shares up as much as 9 percent in premarket trade. Health The company said 56 percent of the patients receiving the drug showed undetectable levels of the virus at four weeks, compared to 20 percent of patients who received the dummy drug. Anadys said, in the trial its key drug was given in combination with pegylated interferon and ribavirin, which is the current standard of care, at a dosage level of 200 milligram bid and analyzed at four weeks. An independent Data Monitoring Committee has recommended escalating to the second dose level, 400 mg bid, the company said in a statement. Anadys said there were eight patients who reported rash through the interim analysis data, seven mild and one moderate, adding that there were no discontinuations due to
